Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 169

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Resveratrol as a Pan-HDAC Inhibitor Alters the Acetylation Status of Jistone Proteins in Human-Derived Hepatoblastoma Cells

Open access
Venturelli, Sascha, Berger, Alexander, Böcker, Alexander, Busch, Christian, Weiland, Timo, Noor, Seema, Leischner, Christian, Schleicher, Sabine, Mayer, Mascha, Weiss, Thomas S., Bischoff, Stephan C., Lauer, Ulrich M., Bitzer, Michael · 2013 · PLoS ONE

Abstract

The polyphenolic alcohol resveratrol has demonstrated promising activities for the prevention and treatment of cancer. Different modes of action have been described for resveratrol including the activation of sirtuins, which represent the class III histone deacetylases (HDACs). However, little is known about the activity of resveratrol on the classical HDACs of class I, II and IV, although these classes are involved in cancer development or progression and inhibitors of HDACs (HDACi) are currently under investigation as promising novel anticancer drugs. We could show by in silico docking studies that resveratrol has the chemical structure to inhibit the activity of different human HDAC enzymes. In vitro analyses of overall HDAC inhibition and a detailed HDAC profiling showed that resveratrol inhibited all eleven human HDACs of class I, II and IV in a dose-dependent manner. Transferring this molecular mechanism into cancer therapy strategies, resveratrol treatment was analyzed on solid tumor cell lines. Despite the fact that hepatocellular carcinoma (HCC) is known to be particularly resistant against conventional chemotherapeutics, treatment of HCC with established HDACi already has shown promising results. Testing of resveratrol on hepatoma cell lines HepG2, Hep3B and HuH7 revealed a dose-dependent antiproliferative effect on all cell lines. Interestingly, only for HepG2 cells a specific inhibition of HDACs and in turn a histone hyperacetylation caused by resveratrol was detected. Additional testing of human blood samples demonstrated a HDACi activity by resveratrol ex vivo. Concluding toxicity studies showed that primary human hepatocytes tolerated resveratrol, whereas in vivo chicken embryotoxicity assays demonstrated severe toxicity at high concentrations. Taken together, this novel pan-HDACi activity opens up a new perspective of resveratrol for cancer therapy alone or in combination with other chemotherapeutics. Moreover, resveratrol may serve as a lead structure for chemical optimization of bioavailability, pharmacology or HDAC inhibition.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0073097

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 62

  1. GJ Soleas, 1997, Resveratrol: a molecule whose time has come? and gone?, Clin Biochem, 30, 91, 10.1016/S0009-9120(96)00155-5 · DOI · Paper page
  2. J Leiro, 2004, In vitro effects of the polyphenols resveratrol, mangiferin and (−)-epigallocatechin-3-gallate on the scuticociliate fish pathogen Philasterides dicentrarchi, Dis Aquat Org, 59, 171, 10.3354/dao059171 · DOI
  3. P Langcake, 1976, The production of resveratrol by Vitis vinifera and other members of the Vitaseae as a response to infection or injury, Physiol Plant Pathol, 9, 77, 10.1016/0048-4059(76)90077-1 · DOI · Paper page
  4. L Creasy, 1988, Phytoalexin production potential of grape berries, J Am Soc Horti Sci, 113, 230, 10.21273/JASHS.113.2.230 · DOI · Paper page
  5. P Kopp, 1988, Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the ‘French paradox’?, Eur J Endocrinol, 138, 619, 10.1530/eje.0.1380619 · DOI · Paper page
  6. AY Sun, 2002, The “French Paradox” and beyond: neuroprotective effects of polyphenols, Free Radical Biol Med, 32, 314
  7. N Kawada, 1998, Effect of antioxidants, resveratrol, quercetin, and N-acetylcysteine, on the functions of cultured rat hepatic stellate cells and Kupffer cells, Hepatology, 27, 1265, 10.1002/hep.510270512 · DOI · Paper page
  8. TL Wadsworth, 1999, Effects of the wine polyphenolics quercetin and resveratrol on pro-inflammatory cytokine expression in RAW 264.7 macrophages, Biochem Pharmacol, 57, 941, 10.1016/S0006-2952(99)00002-7 · DOI · Paper page
  9. TM ElAttar, 1999, Modulating effect of resveratrol and quercetin on oral cancer cell growth and proliferation, Anticancer Drugs, 10, 187, 10.1097/00001813-199902000-00007 · DOI
  10. M Shakibaei, 2003, Resveratrol addiction: To die or not to die, Mol Nutr Food Res, 53, 115, 10.1002/mnfr.200800148 · DOI · Paper page
  11. MC Haigis, 2010, Mammalian sirtuins: biological insights and disease relevance, Annu Rev Pathol, 5, 253, 10.1146/annurev.pathol.4.110807.092250 · DOI · Paper page
  12. S Fulda, 2010, Resveratrol and derivatives for the prevention and treatment of cancer, Drug Discov Today, 15, 757, 10.1016/j.drudis.2010.07.005 · DOI · Paper page
  13. MV Clement, 1998, Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumour cells, Blood, 92, 996, 10.1182/blood.V92.3.996 · DOI · Paper page
  14. I Tinhofer, 2001, Resveratrol, a tumor-suppressive compound from grapes, induces apoptosis via a novel mitochondrial pathway controlled by Bcl-2, Faseb J, 15, 1613, 10.1096/fj.00-0675fje · DOI · Paper page
  15. C Billard, 2002, Comparative antiproliferative and apoptotic effects of resveratrol, epsilon-viniferin and vine-shots derived polyphenols (vineatrols) on chronic B lymphocytic leukaemia cells and normal human lymphocytes, Leuk Lymphoma, 43, 1991, 10.1080/1042819021000015952 · DOI
  16. OP Mgbonyebi, 1998, Antiproliferative effect of synthetic resveratrol on human breast epithelial cells, Int J Oncol, 12, 865
  17. F Wolter, 2001, Downregulation of the cyclin D1/Cdk4 complex occurs during resveratrol-induced cell cycle arrest in colon cancer cell lines, J Nutr, 131, 2197, 10.1093/jn/131.8.2197 · DOI · Paper page
  18. XZ Ding, 2002, Resveratrol inhibits proliferation and induces apoptosis in human pancreatic cancer cells, Pancreas, 25, 71, 10.1097/00006676-200211000-00024 · DOI
  19. O Holian, 2002, Inhibition of gastric cancer cell proliferation by resveratrol: role of nitric oxide, Am J Physiol Gastrointest Liver Physiol, 282, 809, 10.1152/ajpgi.00193.2001 · DOI
  20. M Kampa, 2000, Wine antioxidant polyphenols inhibit the proliferation of human prostate cancer cell lines, Nutr Cancer, 37, 223, 10.1207/S15327914NC372_16 · DOI · Paper page
  21. YA Kim, 2003, Involvement of p21WAF1/CIP1, pRB, Bax and NFkappaB in induction of growth arrest and apoptosis by resveratrol in human lung carcinoma A549 cells, Int J Oncol, 23, 1143
  22. N Ahmad, 2001, Resveratrol causes WAF-1/p21-mediated G(1)-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells, Clin Cancer Res, 7, 1466
  23. Y Kozuki, 2001, Resveratrol suppresses hepatoma cell invasion independently of its anti-proliferative action, Cancer Lett, 167, 151, 10.1016/S0304-3835(01)00476-1 · DOI
  24. PL Kuo, 2002, Resveratrol- induced apoptosis is mediated by p53-dependent pathway in HepG2 cells, Life Sci, 72, 23, 10.1016/S0024-3205(02)02177-X · DOI · Paper page
  25. MR Acharya, 2005, Rational development of histone deacetylase inhibitors as anticancer agents: a review, Mol Pharmacol, 68, 917, 10.1124/mol.105.014167 · DOI · Paper page
  26. L Ellis, 2009, Epigenetics in cancer: targeting chromatin modifications, Mol Cancer Ther, 8, 1409, 10.1158/1535-7163.MCT-08-0860 · DOI · Paper page
  27. PA Marks, 2009, Histone deacetylase inhibitors: Potential in cancer therapy, J Cell Biochem, 107, 600, 10.1002/jcb.22185 · DOI · Paper page
  28. WK Kelly, 2002, Histone deacetylase inhibitors: from target to clinical trials, Expert Opin Invest Drugs, 11, 1695, 10.1517/13543784.11.12.1695 · DOI · Paper page
  29. M Esteller, 2002, Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours, J Pathol, 196, 1, 10.1002/path.1024 · DOI · Paper page
  30. M Duvic, 2007, Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL), Blood, 109, 31, 10.1182/blood-2006-06-025999 · DOI · Paper page
  31. C Campas-Moya, 2009, Romidepsin for the treatment of cutaneous T-cell lymphoma, Drugs Today, 45, 787, 10.1358/dot.2009.45.11.1437052 · DOI
  32. D Dayangaç-Erden, 2009, Histone deacetylase inhibition activity and molecular docking of (e)-resveratrol: its therapeutic potential in spinal muscular atrophy, Chem Biol Drug Des, 73, 355, 10.1111/j.1747-0285.2009.00781.x · DOI
  33. WE Thasler, 2003, Charitable State-Controlled Foundation Human Tissue and Cell Research: Ethic and Legal Aspects in the Supply of Surgically Removed Human Tissue For Research in the Academic and Commercial Sector in Germany, Cell Tissue Bank, 4, 49, 10.1023/A:1026392429112 · DOI
  34. WE Thasler, 2006, Human tissue for in vitro research as an alternative to animal experiments: a charitable "honest broker" model to fulfil ethical and legal regulations and to protect research participants, Altern Lab Anim, 34, 387, 10.1177/026119290603400411 · DOI
  35. P Skehan, 1990, New colorimetric cytotoxicity assay for anticancer-drug screening, J Natl Cancer Inst, 82, 1107, 10.1093/jnci/82.13.1107 · DOI · Paper page
  36. V Hamburger, 1951, A series of normal stages in the development of the chick embryo, Dev Dyn, 195, 231, 10.1002/aja.1001950404 · DOI · Paper page
  37. S Fechner, 2008, The chick embryo as a model for intrauterine ultrasound-guided heart intervention, Ultrasound Obstet Gynecol, 31, 277, 10.1002/uog.5244 · doi:10.1002/uog.5244
  38. C Busch, 2008, Noggin blocks invasive growth of murine B16-F1 melanoma cells in the optic cup of the chick embryo, Int J Cancer, 122, 526, 10.1002/ijc.23139 · DOI
  39. Berger A, Venturelli S, Kallnischkies M, Böcker A, Busch C, <etal>et al</etal>.. (2012) Kaempferol, a new nutrition-derived pan-inhibitor of human histone deacetylases. J Nutr Biochem, in press. · DOI
  40. YA Abassi, 2009, Kinetic cell-based morphological screening: prediction of mechanism of compound action and off-target effects, Chem Biol, 16, 712, 10.1016/j.chembiol.2009.05.011 · DOI · Paper page
  41. T Weiland, 2012, Kinetic Tracking of Therapy-Induced Senescence Using the Real-Time Cell Analyzer SP System, ASSAY and Drug Development Technologies, 10, 289, 10.1089/adt.2011.0402 · DOI
  42. TK Lee, 2002, Doxorubicin-induced apoptosis and chemosensitivity in hepatoma cell lines, Cancer Chemother Pharmacol, 49, 78, 10.1007/s00280-001-0376-4 · doi:10.1007/s00280-001-0376-4
  43. E Menegola, 2006, Inhibition of histone deacetylase as a new mechanism of teratogenesis, Birth Defects Research Part C: Embryo Today: Reviews, 78, 345, 10.1002/bdrc.20082 · DOI
  44. SM Meeran, 2010, Epigenetic targets of bioactive dietary components for cancer prevention and therapy, Clin Epigenetics, 1, 101, 10.1007/s13148-010-0011-5 · DOI · Paper page
  45. E Ho, 2010, Dietary manipulation of histone structure and function, World Rev Nutr Diet, 101, 95, 10.1159/000314514 · DOI
  46. S Chung, 2010, Regulation of SIRT1 in cellular functions: role of polyphenols, Arch Biochem Biophys, 501, 79, 10.1016/j.abb.2010.05.003 · DOI · Paper page
  47. LK Park, 2011, Nutritional influences on epigenetics and age-related disease, Proc Nutr Soc, 4, 1
  48. RH Dashwood, 2006, Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention?, Carcinogenesis, 27, 344, 10.1093/carcin/bgi253 · DOI · Paper page
  49. G Boily, 2009, SirT1-null mice develop tumors at normal rates but are poorly protected by resveratrol, Oncogene, 28, 2882, 10.1038/onc.2009.147 · DOI
  50. Y Hu, 2011, The controversial links among calorie restriction, SIRT1, and resveratrol, Free Radical Biology and Medicine, 51, 250, 10.1016/j.freeradbiomed.2011.04.034 · DOI
  51. B Liu, 2012, Resveratrol rescues SIRT1-dependent adult stem cell decline and alleviates progeroid features in laminopathy-based progeria, Cell Metab, 16, 738, 10.1016/j.cmet.2012.11.007 · DOI · Paper page
  52. F Spallotta, 2013, A nitric oxide-dependent cross-talk between class I and III histone deacetylases accelerates skin repair, J Biol Chem, 288, 11004, 10.1074/jbc.M112.441816 · DOI
  53. ME Juan, 2010, Quantification of trans-resveratrol and its metabolites in rat plasma and tissues by HPLC, J Pharm Biomed Anal, 51, 391, 10.1016/j.jpba.2009.03.026 · DOI · Paper page
  54. H Colom, 2011, Population pharmacokinetic modeling of trans-resveratrol and its glucuronide and sulfate conjugates after oral and intravenous administration in rats, Pharm Res, 28, 1606, 10.1007/s11095-011-0395-8 · DOI
  55. D Colin, 2008, Antiproliferative activities of resveratrol and related compounds in human hepatocyte derived HepG2 cells are associated with biochemical cell disturbance revealed by fluorescence analyses, Biochimie, 90, 1674, 10.1016/j.biochi.2008.06.006 · DOI
  56. PC Liao, 2010, Resveratrol arrests cell cycle and induces apoptosis in human hepatocellular carcinoma Huh-7 cells, J Med Food, 13, 1415, 10.1089/jmf.2010.1126 · DOI
  57. Aldana-Masangkay GI, Sakamoto KM (2011) The role of HDAC6 in cancer. J Biomed Biotechnol DOI: 875824. · DOI · Paper page
  58. S Armeanu, 2005, Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357, J Hepatol, 42, 210, 10.1016/j.jhep.2004.10.020 · DOI
  59. S Venturelli, 2007, Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma, Cancer, 109, 2132, 10.1002/cncr.22652 · DOI
  60. T Walle, 2004, High absorption but very low bioavailability of oral resveratrol in humans. High absorption but very low bioavailability of oral resveratrol in humans, Drug Metab Dispos, 32, 1377, 10.1124/dmd.104.000885 · DOI · Paper page
  61. DJ Boocock, 2007, Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent, Cancer Epidemiol Biomarkers Prev, 16, 1246, 10.1158/1055-9965.EPI-07-0022 · DOI · Paper page
  62. M Ndiaye, 2011, Resveratrol in cancer management: where are we and where we go from here?, Ann N Y Acad Sci, 1215, 144, 10.1111/j.1749-6632.2010.05851.x · DOI

Cited by

See all 169

Metadata

Authors
Venturelli, S., Berger, A., Böcker, A., Busch, C., Weiland, T., Noor, S., Leischner, C., Schleicher, S., Mayer, M., Weiss, T. S., Bischoff, S. C., Lauer, U. M., & Bitzer, M.
Venue
PLoS ONE
Published
2013-08-30
Volume
8
Issue
8
Pages
e73097
ISSN
1932-6203 (ISSN-L)
OpenAlex
W1968076212
Cited by
169
References
4
FWCI
5.51
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Resveratrol as a Pan-HDAC Inhibitor Alters the Acetylation Status of Jistone Proteins in Human-Derived Hepatoblastoma Cells. https://app.cochat.ai/papers/10.1371/journal.pone.0073097
The paper
Venturelli, S., Berger, A., Böcker, A., Busch, C., Weiland, T., Noor, S., Leischner, C., Schleicher, S., Mayer, M., Weiss, T. S., Bischoff, S. C., Lauer, U. M., & Bitzer, M. (2013). Resveratrol as a Pan-HDAC Inhibitor Alters the Acetylation Status of Jistone Proteins in Human-Derived Hepatoblastoma Cells. PLoS ONE. https://doi.org/10.1371/journal.pone.0073097

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.